Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC

Up to date information from the section 3 BREAKWATER trial confirmed that combining Braftovi (encorafenib) and Erbitux (cetuximab) with mFOLFOX6 chemotherapy (modified fluorouracil, leucovorin and oxaliplatin) elicited a statistically important and clinically significant enchancment in progression-free survival versus standard-of-care remedy within the first-line therapy for sufferers with metastatic colorectal most cancers (mCRC) harboring BRAF V600E mutations.

Findings have been offered in a press briefing forward of the 2025 ASCO Annual Assembly and revealed within the New England Journal of Drugs. Of the 236 sufferers handled with Braftovi plus Erbitux and mFOLFOX6, the median PFS was 12.8 at a median follow-up of 16.8 months. This quantity was 7.1 months at a median follow-up of 9.8 months among the many 243 sufferers given standard-of-care therapy.

Moreover, Braftovi plus Erbitux and mFOLFOX6 generated a median total survival of 30.3 months versus 15.1 months with standard-of-care. The estimated 12- and 24-month total survival charges within the experimental arm have been 80.1% and 52.0%, respectively. These respective charges have been 66.0% and 29.0% within the standard-of-care therapy arm.

“Braftovi [in combination with] Erbitux and mFOLFOX6 — the BREAKWATER routine — is a practice-changing, new standard-of-care for [patients] with mCRC with a BRAF V600E mutation,” lead examine creator Elena Elez, MD, PhD, mentioned in the course of the press briefing.

Elez is an attending doctor within the Gastrointestinal Tumors Service of the Medical Oncology Service at Vall d’Hebron College Hospital and principal investigator of the Gastrointestinal Tumor Group and Endocrine of Vall d’Hebron Instituto de Oncología in Barcelona, Spain.

In December 2024, the FDA granted accelerated approval to Braftovi together with Erbitux and mFOLFOX6 for sufferers with mCRC with a BRAF V600E mutation, as detected by an FDA-approved take a look at. The regulatory determination was based mostly on beforehand reported information from BREAKWATER, which confirmed that among the many first 110 sufferers handled in every arm, the general response fee was 61% for the mixture versus 40% for standard-of-care. The median length of response was 13.9 months and 11.1 months, respectively.

Breaking Down BREAKWATER

The open-label, multicenter examine enrolled sufferers at the least 16 years of age (or at the least 18 years of age, based mostly on the nation), with mCRC who had measurable illness per RECIST 1.1 standards and had not acquired prior systemic remedy within the metastatic setting. The presence of a BRAF V600E mutation was required, per native or central testing. Sufferers additionally wanted to have an ECOG efficiency standing of 0 or 1, together with sufficient bone marrow, hepatic and renal perform.

Combining Braftovi and Erbitux with mFOLFOX6 elicited a statistically important and clinically significant enchancment in progression-free survival versus standard-of-care remedy within the first-line therapy for sufferers with mCRC harboring BRAF V600E mutations.

Key exclusion standards comprised prior publicity to BRAF or EGFR inhibitors; symptomatic mind metastases; microsatellite instability-high/mismatch repair-deficient tumors, except sufferers have been ineligible for immune checkpoint inhibitors; and RAS-mutated illness.

Investigators randomly assigned 637 sufferers style to obtain Braftovi plus Erbitux alone (158 sufferers); Braftovi together with Erbitux and chemo (236 sufferers); or standard-of-care (243 sufferers). Enrollment to the Braftovi/Erbitux alone cohort was stopped following a protocol modification and subsequently enrolled sufferers have been randomly assigned between the opposite two arms.

Therapy within the standard-of-care arm included mFOLFOX6, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin and irinotecan), or CAPOX (capecitabine and oxaliplatin) with or with out Avastin (bevacizumab).

Stratification elements included area (United States/Canada versus Europe versus remainder of world) and ECOG efficiency standing (0 versus 1).

Total response fee and progression-free survival per blinded impartial central assessment served because the trial’s twin major finish factors. Total survival was a key secondary finish level.

Further Efficacy and Security Findings

Knowledge from the cohort of sufferers who acquired Braftovi plus Erbitux with out chemo confirmed that the median progression-free survival was 6.8 months and the median total survival was 19.5 months.

Up to date response information demonstrated that the general response fee for Braftovi plus Erbitux and chemo was 65.7%; the charges of full response, partial response, steady illness and progressive illness on this arm have been 4.7%, 61.0%, 21.2% and three.4%, respectively. Within the standard-of-care arm, the general response fee was 37.4% (95% CI, 31.6%-43.7%) with an entire response fee of three.3%, a partial response fee of 34.2%, a steady illness fee of 35.0% and a progressive illness fee of 8.6%. Within the Braftovi/Erbitux alone arm, the ORR was 45.6% with full, partial response, steady illness and progressive charges of 1.9%, 43.7%, 36.1% and seven.6%, respectively.

The median time to response was 7.0 weeks (vary, 5.1-103.6) for Braftovi/Erbitux/mFOLFOX6, 7.3 weeks (vary, 5.4-48.0) for standard-of-care and 6.6 weeks (vary, 4.3-86.4) for Braftovi/Erbitux. The median length of response was 13.9 months, 10.8 months and seven.0 months, respectively.

Within the Braftovi/Erbitux/chemo arm, the 6- and 12-month length of response charges have been 71.0% and 34.8%, respectively. These respective charges have been 41.8% and 17.6% within the standard-of-care arm; they have been 40.3% and 20.8%, respectively, for Braftovi/Erbitux alone.

At information cutoff, 28.4% of sufferers within the Braftovi/Erbitux/chemo arm remained on therapy in contrast with 6.6% within the standard-of-care arm and seven.6% of sufferers within the Braftovi/Erbitux arm. Subsequent remedy was administered to 63.9% of sufferers within the Braftovi/Erbitux/chemo group versus 61.2% within the standard-of-care group and 73.3% within the Braftovi/Erbitux group. A BRAF inhibitor–based mostly routine was given as subsequent remedy to 71.9% of the 139 sufferers within the standard-of-care arm who acquired further therapy.

The median time to second illness development or loss of life was 20.7 months within the Braftovi/Erbitux/chemo arm, 12.7 months within the standard-of-care arm and 14.3 months within the Braftovi/Erbitux arm.

Concerning security, the Braftovi plus Erbitux and chemo routine was typically tolerable with a constant security profile. No substantial will increase in chemotherapy dose reductions or discontinuation have been noticed in contrast with the standard-of-care arm.

Any-grade unwanted side effects have been reported in all sufferers within the Braftovi/Erbitux/chemo arm, 99.1% of sufferers within the standard-of-care arm and 97.4% of sufferers within the Braftovi/Erbitux arm. The charges of grade 3 (extreme) or grade 4 (life-threatening) unwanted side effects have been 81.5%, 66.8% and 42.5%, respectively. The respective charges of grade 5 (loss of life) occasions have been 4.3%, 4.4% and a pair of.6%. One grade 5 aspect impact within the standard-of-care arm was deemed therapy associated.

The commonest grade 1/2 unwanted side effects included nausea (mixture, 51%; standard-of-care, 46%), anemia (31%; 21%), diarrhea (41%; 46%), decreased urge for food (35%; 26%), vomiting (32%; 20%), decreased neutrophil depend (15%; 12%), arthralgia (29%; 5%), rash (29%; 4%), asthenia (24%; 14%), pyrexia (27%; 15%), peripheral neuropathy (20%; 20%), constipation (27%; 22%), peripheral sensory neuropathy (20%; 20%) and fatigue (24%; 24%).¹

Probably the most steadily reported grade 3/4 unwanted side effects included nausea (mixture, 3%; standard-of-care, 4%), anemia (15%; 4%), diarrhea (1%; 5%), decreased urge for food (2%; 1%), vomiting (4%; 2%), decreased neutrophil depend (19%; 17%), arthralgia (3%; <1%), rash (1%; 0%), asthenia (5%; 1%), pyrexia (2%; <1%), peripheral neuropathy (8%; 4%), constipation (<1%; <1%), peripheral sensory neuropathy (7%; 4%) and fatigue (3%; 4%).

Unintended effects led to everlasting discontinuation of any examine therapy in 26.7% of sufferers within the Braftovi/Erbitux/chemo arm, 17.5% of sufferers within the standard-of-care arm and 13.1% of sufferers within the Braftovi/Erbitux arm. Unintended effects led to dose reductions of any therapy in 65.5%, 54.1% and 10.5% of sufferers, respectively. The charges of unwanted side effects resulting in dose reductions have been 59.9% within the Braftovi/Erbitux/chemo arm and 54.1% within the standard-of-care arm. Unintended effects led to the discontinuation of chemotherapy (with or with out Avastin) in 20.7% of the sufferers within the Braftovi/Erbitux/chemo group versus 17.5% within the standard-of-care group.

References

• Elez E, Yoshino T, Shen L, et al. First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal most cancers (BREAKWATER): progression-free survival and up to date total survival analyses. J Clin Oncol. 2025;43(suppl 17):LBA3500. doi:10.1200/JCO.2025.43.17_suppl.LBA3500
• Elez E, Yoshino T, Shen L, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal most cancers. N Engl J Med. Printed on-line Could 30, 2025. doi:10.1056/NEJMoa2501912

For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.